Lipohep (Heparin Sodium)

Lipohep is an anticoagulant that acts on the coagulation cascade to reduce thrombotic events.

• Venous thromboembolism: prevents new clot formation and recurrence in affected patients.
• Deep vein thrombosis prophylaxis: lowers the incidence of DVT in surgical or immobilised individuals.
• Pulmonary embolism prevention: inhibits clot propagation to the pulmonary arteries, reducing embolic risk.

• Heparin Sodium binds to antithrombin III, enhancing its inhibitory effect on thrombin (factor IIa) and factor Xa. This potentiation accelerates the inactivation of key clotting enzymes, thereby interrupting the conversion of fibrinogen to fibrin and preventing thrombus development.

Lipohep may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Injection site bruising or hematoma.
• Minor bleeding such as nosebleeds or gum bleeding.
• Local pain or erythema at the injection site.
• Transient thrombocytopenia.
• Urticaria or mild skin rash.

Serious or Rare Side Effects

• Heparin‑induced thrombocytopenia (HIT), a potentially life‑threatening immune reaction.
• Major hemorrhage, including intracranial or gastrointestinal bleeding.
• Spinal or epidural hematoma when administered near the spine.
• Anaphylactic shock or severe allergic reaction.
• Osteopenia with prolonged high‑dose therapy.

Before initiating Lipohep therapy, clinicians should assess individual risk factors and monitor patients closely.

• Monitor coagulation parameters: check aPTT or anti‑Xa levels as directed.
• Assess bleeding risk: evaluate history of hemorrhage or active bleeding.
• Review renal and hepatic function: adjust therapy if organ impairment is present.
• Avoid concurrent anticoagulants unless medically justified: limit use with warfarin, DOACs, or thrombolytics.
• Store at room temperature: keep in original container, protect from moisture and light.

Heparin Sodium can interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Concurrent use with other anticoagulants (e.g., warfarin, direct oral anticoagulants): markedly increased bleeding risk.
• Administration with thrombolytic agents (e.g., alteplase): heightened hemorrhagic complications.
• Combination with non‑steroidal anti‑inflammatory drugs (NSAIDs): potentiates bleeding.

Moderate Interactions (Monitor Closely)

• Co‑administration with antiplatelet agents (e.g., aspirin, clopidogrel): monitor for additive bleeding.
• Use with systemic corticosteroids: may increase gastrointestinal bleeding risk.
• Interaction with ACE inhibitors: observe for rare bleeding events.